Thrombotic microangiopathies (TMAs) are multiple disease entities with different etiopathogeneses, characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytosis, variable symptoms includ...
Objective: Cancer, one of the principal causes of death, is a global social health problem. Autoantibodies developed against the organism’s self-antigens are detected in the sera of subjects with cancer. In recent years...
To the Editor,
Dr. Köseler and her colleagues reported the presence of δ- thalassemia in 3 out of 12 patients carrying the β-thalassemia trait with low HbA2 in the recent issue of this journal without giving any explana...
Objective: High-doses of melphalan treatment with autologous stem cell transplantation in multiple myeloma (MM) remains a major treatment modality in suitable patients. A minimal dose of 2x106/kg CD34+ cells is preferred...
Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies
Thrombotic microangiopathies (TMAs) are multiple disease entities with different etiopathogeneses, characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytosis, variable symptoms includ...
Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia
Objective: Cancer, one of the principal causes of death, is a global social health problem. Autoantibodies developed against the organism’s self-antigens are detected in the sera of subjects with cancer. In recent years...
Low HbA2 Level in β-Thalassemia Trait
To the Editor, Dr. Köseler and her colleagues reported the presence of δ- thalassemia in 3 out of 12 patients carrying the β-thalassemia trait with low HbA2 in the recent issue of this journal without giving any explana...
Çocuklarda Çok Nadir bir Morluk Nedeni: Otoeritrosit Sensitizasyon Sendromu
Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
Objective: High-doses of melphalan treatment with autologous stem cell transplantation in multiple myeloma (MM) remains a major treatment modality in suitable patients. A minimal dose of 2x106/kg CD34+ cells is preferred...